Circulating the HLA-DR+ T Cell Ratio Is a Prognostic Factor for Recurrence of Patients with Hepatocellular Carcinoma after Curative Surgery

Table 2

Univariate and multivariate Cox regression analyses of risk factors associated with progression-free survival (PFS) after curative surgery for hepatocellular carcinoma.

Variables	HR comparison	UV HR (95% CI)	UV value	MV HR (95% CI)	MV value
Gender	Male vs. female	1.264 (0.710–2.249)	0.425
Age	≥60 vs.<60 years	0.774 (0.491–1.219)	0.269
HbsAg positivity	Yes vs. no	1.499 (0.722–3.113)	0.277
Liver cirrhosis	Yes vs. no	1.535 (0.957–2.463)	0.076
AST/ALT	≥1 vs. <1	1.016 (0.634–1.627)	0.948
GGT level	≥45 U/L vs. <45 U/L	2.104 (1.354–3.271)	0.001	1.692 (1.062–2.696)	0.027
AFP positivity	Yes vs. no	1.648 (1.057–2.568)	0.027	1.371 (0.857–2.194)	0.187
CD3+ T cell ratio	≥77% vs. <77%	0.680 (0.375–1.233)	0.204
CD4+ T cell ratio	≥41.6% vs. <41.6%	1.129 (0.706–1.803)	0.613
CD8+ T cell ratio	≥29.6% vs. <29.6%	0.595 (0.363–0.975)	0.040	0.655 (0.387–1.109)	0.116
HLADR+ T cell ratio	≥5.8% vs.<5.8%	0.512 (0.328–0.799)	0.003	0.465 (0.288–0.750)	0.002
B cell ratio	≥18.2% vs. <18.2%	1.427 (0.861–2.366)	0.168
NK cell ratio	≥25.6% vs. <25.6%	1.063 (0.575–1.956)	0.845
Edmondson grade	III-IV vs. I-II	1.697 (1.095–2.629)	0.018	1.638 (1.006–2.668)	0.047
Largest tumor size	≥5 vs. <5 cm	1.675 (1.044–2.690)	0.033	1.572 (0.930–2.657)	0.091
Microvascular invasion	Yes vs. No	1.440 (0.924–2.246)	0.108
Capsular invasion	Yes vs. No	1.709 (1.103–2.647)	0.016	1.615 (1.010–2.582)	0.045
Prophylactic TACE after surgery	Yes vs. No	1.790 (1.154–2.776)	0.009	1.044 (0.633–1.723)	0.867

AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase; TACE: transcatheter arterial chemoembolization.